O³-methyl-D-ribose | 30724-97-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: O³-methyl-D-ribose
• 英文别名: D-ribo-2,4,5-Trihydroxy-3-methoxy-valeraldehyd；(2R,3R,4R)-2,4,5-trihydroxy-3-methoxypentanal
• CAS: 30724-97-1
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: JNAZNWGFTWHNTH-JKUQZMGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  O³-methyl-D-ribose 、 苯肼 生成 3-O-Methyl-D-arabinose-phenylosazon
  参考文献：
  名称：

  Barker et al., Journal of the Chemical Society, 1955, p. 1327,1330

  摘要：

  DOI：
• 作为产物：
  描述：

  ((3aR,5R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[2,3-d] [1,3]dioxol-5-yl)methanol 在 ion-exchange resin + form> 、 水 作用下， 生成 O³-methyl-D-ribose
  参考文献：
  名称：

  3-O-Methyl-d-allose and a facile route to 2- and 3-O-methyl-d-riboses

  摘要：

  DOI：

  10.1016/s0008-6215(00)84925-3

文献信息

• Chemical synthesis of methoxy nucleosides
  申请人：Ribozyme Pharmaceuticals, Inc.

  公开号：US20030204078A1

  公开（公告）日：2003-10-30

  Process for chemical synthesis of methoxy nucleosides.

  甲氧基核苷化合物的化学合成过程。
• Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
  申请人：RIBOZYME PHARMACEUTICALS, INC.

  公开号：EP1108724A2

  公开（公告）日：2001-06-20

  This invention relates to chemical synthesis of 2'-O-methyl, 3'-O-methyl and 5'-O-methyl nucleosides, incorporation of novel chemical modifications in enzymatic nucleic acid molecules and improved methods for the synthesis of enzymatic nucleic acid molecules.

  本发明涉及 2'-O-甲基、3'-O-甲基和 5'-O-甲基核苷的化学合成、在酶核酸分子中加入新型化学修饰以及改进酶核酸分子的合成方法。
• Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
  申请人：HYBRIDON, INC.

  公开号：EP1393745A1

  公开（公告）日：2004-03-03

  The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3' ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5' end.

  本发明涉及寡核苷酸在免疫疗法中作为免疫刺激剂的治疗用途。更具体地说，本发明提供了用于产生免疫应答或治疗需要免疫刺激的病人的方法中的免疫体。本发明的免疫单体包括至少两个在其 3'端、核苷间连接或功能化核碱基或糖与非核苷酸连接体连接的寡核苷酸，其中至少一个寡核苷酸是免疫刺激寡核苷酸，并具有可访问的 5'端。
• Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
  申请人：IDERA PHARMACEUTICALS, INC.

  公开号：EP1736479A2

  公开（公告）日：2006-12-27

  The present invention relates to immunostimulatory oligonucleotide compounds and their use as immunostimulatory agents in immunotherapy applications.

  本发明涉及免疫刺激寡核苷酸化合物及其作为免疫刺激剂在免疫疗法中的应用。
• Modulation of immunostimulatory properties by small oligonucleotide-based compounds
  申请人：HYBRIDON, INC.

  公开号：EP2060269A2

  公开（公告）日：2009-05-20

  The invention relates to immunology and immunotherapy applications using oligonucleotides as immunostimulatory agents. In particular, the invention relates to immunostimulatory oligonucleotide immunomers, immunomodulatory compositions comprising said immunomodulatory oligonucleotide immunomers, and the use of said immunomodulatory oligonucleotide immunomers for immunotherapy applications.

  本发明涉及使用寡核苷酸作为免疫刺激剂的免疫学和免疫疗法应用。 特别是，本发明涉及免疫刺激寡核苷酸免疫组化物、包含所述免疫调节寡核苷酸免疫组化物的免疫调节组合物，以及所述免疫调节寡核苷酸免疫组化物在免疫疗法中的应用。